Boston Common Asset Management, LLC Grifols Sa Transaction History

Boston Common Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Jan 31, 2022	SELL	$10.21 - $15.27 $4.62 Million - $6.91 Million	-452,266 Closed	0 $0
Q3 2021 Nov 12, 2021	SELL	$14.07 - $17.3 $6.29 Million - $7.73 Million	-446,975 Reduced 49.71%	452,266 $6.61 Million
Q2 2021 Aug 19, 2021	BUY	$16.62 - $18.94 $11.2 Million - $12.8 Million	673,422 Added 298.21%	899,241 $15.6 Million
Q1 2021 May 14, 2021	BUY	$15.15 - $19.78 $399,141 - $521,123	26,346 Added 13.21%	225,819 $3.9 Million
Q4 2020 Feb 05, 2021	BUY	$16.86 - $19.67 $629,754 - $734,713	37,352 Added 23.04%	199,473 $3.68 Million
Q3 2020 Nov 10, 2020	BUY	$15.4 - $20.16 $2.5 Million - $3.27 Million	162,121 New	162,121 $2.81 Million

164

140M

288K

389K

Ticker GRFS
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 678,910,976
Market Cap $5.31B
Description
Grifols, S.A. engages in the procurement, manufacture, preparation, and sale of therapeutic products, primarily hemoderivatives. The company operates through Bioscience, Hospital, Diagnostic, Bio Supplies, and Others divisions. The Bioscience division researches, develops, produces, and markets plasma-derived medicines and other innovative solut...

Get notified when there are updates to the investment portfolio of Boston Common Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boston Common Asset Management, LLC with notifications on news.